Nanosphere Q3 Revenues Plunge 49 Percent on End of Service Contracts
November 03, 2010
Nanosphere Q3 Revenues Plunge 49 Percent on End of Service Contracts
On a conference call, the company's CEO said that Nanosphere has submitted a PMA for its 2C19 assay and plans to submit a new 510(k) submission for its cardiac troponin assay.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Nanosphere Posts Q2 Revenue Rise of 160 Percent but Misses Estimate
July 16, 2012 / GenomeWeb Daily News - Dx Firms GenMark, Nanosphere, CombiMatrix Attribute Q1 Revenue Growth to Sales Efforts
May 14, 2013 / BioArray News - Nanosphere Reaches Distribution, Collaboration Deal with Hitachi; Completes $4.7M Financing
May 14, 2013 / GenomeWeb Daily News - Nanosphere Q1 Revenues Rise 85 Percent; Secures $27M in Financing
May 8, 2013 / GenomeWeb Daily News - CombiMatrix's Q1 Revenues Jump 27 Percent on Prenatal Microarray Testing Demand
May 8, 2013 / GenomeWeb Daily News